Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MK-0608 是一种可口服的体外 HCV 复制抑制剂。在亚基因组复制子测定中,EC50值为 0.3 μM,EC90值为 1.3 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 752 | 现货 | ||
2 mg | ¥ 997 | 现货 | ||
5 mg | ¥ 1,800 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,780 | 现货 | ||
50 mg | ¥ 6,850 | 现货 | ||
100 mg | ¥ 9,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,690 | 现货 |
产品描述 | MK-0608 is an orally bioavailable HCV replication inhibitor in vitro(EC50 = 0.3 μM and EC90=1.3 μM in the subgenomic-replicon assay). |
靶点活性 | HCV replication:(EC50)0.3 μM |
体内活性 | MK-0608 inhibit viral RNA replication in the subgenomic HCV genotype 1b replicon, with a 50% effective concentration (EC(50)) of 0.3 microM (EC(90) = 1.3 microM). A?robust antiviral effect on the administration of MK-0608 to HCV-infected chimpanzees. |
动物实验 | MK-0608 was administered to HCV-infected chimpanzees, resulting in dose- and time-dependent decreases in plasma viral loads.?In separate experiments, chimpanzees dosed for 7 days with MK-0608 at 0.2 and 2 mg per kg of body weight per day by intravenous administration experienced average reductions in viral load of 1.0 and >5 log(10) IU/ml, respectively.?Two other HCV-infected chimpanzees received daily doses of 1 mg MK-0608 per kg via oral administration.?After 37 days of oral dosing, one chimpanzee with a high starting viral load experienced a reduction in viral load of 4.6 log(10), and the viral load in the other chimpanzee fell below the limit of quantification (LOQ) of the HCV TaqMan assay (20 IU/ml).?Importantly, viral load remained below the LOQ throughout the duration of dosing and for at least 12 days after dosing ended. |
分子量 | 280.28 |
分子式 | C12H16N4O4 |
CAS No. | 443642-29-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (98.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5679 mL | 17.8393 mL | 35.6786 mL | 89.1965 mL |
5 mM | 0.7136 mL | 3.5679 mL | 7.1357 mL | 17.8393 mL | |
10 mM | 0.3568 mL | 1.7839 mL | 3.5679 mL | 8.9197 mL | |
20 mM | 0.1784 mL | 0.892 mL | 1.7839 mL | 4.4598 mL | |
50 mM | 0.0714 mL | 0.3568 mL | 0.7136 mL | 1.7839 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MK-0608 443642-29-3 Microbiology/Virology Proteases/Proteasome HCV Protease inhibit Inhibitor HCV MK0608 Hepatitis C virus MK 0608 inhibitor